In patients with advanced solid tumors, a new possible epigenetic treatment targeting the enzyme arginine methyl transferase 5 (PRMT5) has shown encouraging early results. Researchers performed a phase I clinical study in 90 patients with advanced solid tumors who had previously undergone therapy to assess the safety and preliminary effectiveness of JNJ-64619178, a selective PRMT5 inhibitor. The medication was usually well accepted, with just minor adverse effects, especially hematologic and gastrointestinal problems. Most notably, JNJ-64619178 demonstrated early anticancer efficacy, particularly in individuals suffering from adenoid cystic carcinoma, a rare salivary gland cancer with few therapeutic alternatives. The researchers determined the drug’s maximum tolerable dosage and proposed a phase II trial dose. The findings promote additional research into JNJ-64619178 as a potential novel targeted therapy.

To know more: About the original article click here.